{
    "nctId": "NCT00398567",
    "briefTitle": "A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast Cancer",
    "officialTitle": "A Phase I/II Study of HKI-272 in Combination With Trastuzumab (Herceptin) in Subjects With Advanced Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Advanced Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1, PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 45,
    "primaryOutcomeMeasure": "16-week Progression-free Survival (PFS) Rate",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Pathologic diagnosis of breast cancer with current stage IIIB, IIIC or IV not curable by available therapy\n* Progression following at least one Herceptin-containing cytotoxic chemotherapy regimen (neoadjuvant, adjuvant, or metastatic setting)\n* HER2 positive breast cancer\n* At least one measurable target lesion\n* Adequate performance status\n* Adequate cardiac, kidney, and liver function\n* Adequate blood counts\n* Willingness of all subjects who are not surgically sterile or post menopausal to use acceptable methods of birth control\n\nExclusion Criteria:\n\n* More than 3 prior cytotoxic chemotherapy regimens for locally advanced or metastatic disease\n* Major surgery, chemotherapy, radiotherapy, investigational agents, Herceptin or other cancer therapy within 2 weeks of treatment day 1\n* Prior treatment with anthracyclines with cumulative dose of \\>400 mg/m\\^2\n* Extensive visceral disease\n* Active central nervous system metastases\n* Pregnant or breast feeding women\n* Significant chronic or recent acute gastrointestinal disorder with diarrhea as a major symptom\n* Prior exposure to HKI-272 or other HER2 targeted agents (except Herceptin and Tykerb)\n* Significant cardiac disease or dysfunction\n* History of life-threatening hypersensitivity to Herceptin\n* Inability or unwillingness to swallow HKI-272 capsules\n* Any other cancer within 5 years with the exception of contralateral breast cancer, adequately treated cervical carcinoma in situ, or adequately treated basal or squamous cell carcinoma of the skin",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}